

Var2 Pharmaceuticals ApS

c/o Cobis A/S, Ole Maaløes Vej 3, 2200 København N

Company reg. no. 34 62 19 42

Annual report

2020

The annual report has been submitted and approved by the general meeting on 16 June 2021.

Ali El-Salanti
Chairman of the meeting

Contents

	<u>Page</u>
Reports	
Management's report	1
Independent auditor's report	2
Management commentary	
Company information	5
Financial highlights	6
Management commentary	7
Financial statements 1 January - 31 December 2020	
Accounting policies	8
Income statement	12
Statement of financial position	13
Statement of changes in equity	15
Notes	16

Notes to users of the English version of this document:

- This document is a translation of a Danish version of the document. In the event of any dispute regarding the interpretation of any part of the document, the Danish version of the document shall prevail.
- To ensure the greatest possible applicability of this document, IAS/IFRS English terminology has been used.
- Please note that decimal points remain unchanged from Danish version of the document. This means that DKK 146.940 corresponds to the English amount of DKK 146,940, and that 23,5 % corresponds to 23.5 %.

Management's report

Today, the board of directors and the executive board have presented the annual report of Var2 Pharmaceuticals ApS for the financial year 2020.

The annual report has been presented in accordance with the Danish Financial Statements Act.

We consider the accounting policies appropriate and, in our opinion, the financial statements provide a fair presentation of the company's assets, equity and liabilities, and financial position at 31 December 2020 and of the company's results of activities in the financial year 1 January – 31 December 2020.

We are of the opinion that the management commentary presents a fair account of the issues dealt with.

We recommend that the annual report be approved by the general meeting.

København N, 16 June 2021

Executive board

Ali El-Salanti

Mads Daugaard

Board of directors

Mads Daugaard
Chairman

Peter Schröcksnadel

Poul Henrik Bredahl Sørensen

Ali El-Salanti

Thor Grundtvig Theander

Independent auditor's report

To the shareholders of Var2 Pharmaceuticals ApS

Opinion

We have audited the financial statements of Var2 Pharmaceuticals ApS for the financial year 1 January - 31 December 2020, which comprise accounting policies, income statement, statement of financial position, statement of changes in equity and notes. The financial statements have been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements present a fair view of the company's assets, equity and liabilities, and financial position at 31 December 2020 and of the results of the company's activities for the financial year 1 January - 31 December 2020 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with international standards on auditing and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the section "Auditor's responsibilities for the audit of the financial statements". We are independent of the company in accordance with international ethical requirements for auditors (IESBA's Code of Ethics), and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation of financial statements that provide a fair view in accordance with the Danish Financial Statements Act. Management is also responsible for such internal control as the management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements, as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor's report including an opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with international standards on auditing, and the additional requirements applicable in Denmark, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Independent auditor's report

As part of an audit conducted in accordance with international standards on auditing, and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of the internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's preparation of the financial statements using the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists arising from events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and contents of the financial statements, including disclosures in notes, and whether the financial statements reflect the underlying transactions and events in a manner that presents a fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the internal control that we identify during our audit.

Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we express no assurance opinion thereon.

Independent auditor's report

In connection with our audit of the financial statements, it is our responsibility to read the management commentary and to consider whether the management commentary is materially inconsistent with the financial statements or the evidence obtained during the audit, or whether it otherwise appears to contain material misstatement.

Furthermore, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we believe that management commentary is consistent with the financial statements and that it has been prepared in accordance with the provisions of the Danish Financial Statement Act. We did not discover any material misstatement in the management commentary.

Glostrup, 16 June 2021

PKF Munkebo Vindelev

State Authorised Public Accountants
Company reg. no. 14 11 92 99

Kasper Vindelev
State Authorised Public Accountant
mne29389

Company information

The company	Var2 Pharmaceuticals ApS c/o Cobis A/S Ole Maaløes Vej 3 2200 København N
	Company reg. no. 34 62 19 42 Established: 1 June 2012 Domicile: The City of Copenhagen Financial year: 1 January - 31 December 9th financial year
Board of directors	Mads Daugaard, Chairman Peter Schröcksnadel Poul Henrik Bredahl Sørensen Ali El-Salanti Thor Grundtvig Theander
Executive board	Ali El-Salanti Mads Daugaard
Auditors	PKF Munkebo Vindelev, Statsautoriseret Revisionsaktieselskab Hovedvejen 56 2600 Glostrup
Bankers	Danske Bank, Holmens Kanal 2, 1090 København K
Parent company	Oncomal ApS

Financial highlights

DKK in thousands.	<u>2020</u>	<u>2019</u>	<u>2018</u>	<u>2017</u>	<u>2016</u>
Income statement:					
Gross profit	-3.413	-4.730	-1.958	-3.958	-1.633
Profit from operating activities	-6.871	-8.251	-4.846	-5.589	-2.365
Net financials	-163	-24	52	-17	-8
Net profit or loss for the year	-5.390	-6.851	-3.968	-4.379	-1.857
Statement of financial position:					
Balance sheet total	44.763	51.106	56.506	14.193	10.172
Equity	42.900	48.290	55.141	13.660	9.855
Employees:					
Average number of full-time employees	8	8	6	3	0

Management commentary

The principal activities of the company

The company is founded to directly or indirectly through ownership of other companies, develop products for diagnosis and treatment of cancer or related activities.

Development in activities and financial matters

The gross loss for the year totals DKK -3.413.000 against DKK -4.730.000 last year. Income or loss from ordinary activities after tax totals DKK -5.390.000 against DKK -6.851.000 last year.

Considering the state of the world with COVID-19 lockdown of several activities, the management considers the results of 2020 satisfactory. During the shutdown several employees was dedicated to making the COVID-19 vaccine, now in clinical testing. This has been fully compensated by the COVID-19 project covering their salaries at UCPH in this period. VAR2pharma is dedicated to develop two products, a drug conjugate and a bispecific immunotherapy. The focus for the drug conjugate has been to extend half-life and to define new drug linkers. We have successfully extended half-life from minutes to hours using common half extension technologies, further we have defined a set of linkers to be used moving the VDC forward for clinical use. For the bispecific we have demonstrated strong proof of concept in a wide range of animal models, including breast cancer, melanoma and colon. The focus has been to transition the compound for human use and currently we are working on process development for GMP.

Events occurring after the end of the financial year

No events have occurred subsequent to the balance sheet date, which would have material impact on the financial position of the company.

Accounting policies

The annual report for Var2 Pharmaceuticals ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises.

The accounting policies are unchanged from last year, and the annual report is presented in DKK.

Recognition and measurement in general

Income is recognised in the income statement concurrently with its realisation, including the recognition of value adjustments of financial assets and liabilities. Likewise, all costs are recognised in the income statement, including depreciations amortisations, writedowns for impairment, provisions, and reversals due to changes in estimated amounts previously recognised in the income statement.

Assets are recognised in the statement of financial position when it seems probable that future economic benefits will flow to the company and the value of the asset can be reliably measured.

Liabilities are recognised in the statement of financial position when it is seems probable that future economic benefits will flow out of the company and the value of the liability can be reliably measured.

Assets and liabilities are measured at cost at the initial recognition. Hereafter, assets and liabilities are measured as described below for each individual accounting item.

Certain financial assets and liabilities are measured at amortised cost, allowing a constant effective interest rate to be recognised during the useful life of the asset or liability. Amortised cost is recognised as the original cost less any payments, plus/less accrued amortisations of the difference between cost and nominal amount. In this way, capital losses and gains are allocated over the useful life of the liability.

Upon recognition and measurement, allowances are made for such predictable losses and risks which may arise prior to the presentation of the annual report and concern matters that exist on the reporting date.

Foreign currency translation

Transactions in foreign currency are translated by using the exchange rate prevailing at the date of the transaction. Differences in the rate of exchange arising between the rate at the date of transaction and the rate at the date of payment are recognised in the profit and loss account as an item under net financials. If currency positions are considered to hedge future cash flows, the value adjustments are recognised directly in equity in a fair value reserve.

Receivables, payables, and other foreign currency monetary items are translated using the closing rate. The difference between the closing rate and the rate at the time of the occurrence or initial recognition in the latest financial statements of the receivable or payable is recognised in the income statement under financial income and expenses.

Accounting policies

Income statement

Gross loss

Gross loss comprises research and development costs, other operating income and other external costs.

Research and development costs comprise of external costs for research and development activities.

Other operating income comprises items of a secondary nature as regards the principal activities of the enterprise, including profit from the disposal of intangible and tangible assets.

Other external costs comprise costs for sales, premises and administration.

Staff costs

Staff costs include salaries and wages, including holiday allowances, pensions, and other social security costs, etc., for staff members. Staff costs are less government reimbursements.

Depreciation, amortisation, and writedown for impairment

Depreciation, amortisation, and writedown for impairment comprise depreciation on, amortisation of, and writedown for impairment of intangible and tangible assets, respectively.

Financial income and expenses

Financial income and expenses are recognised in the income statement with the amounts concerning the financial year. Financial income and expenses comprise interest income and expenses, realised and unrealised capital gains and losses relating to debt and transactions in foreign currency.

Tax on net profit or loss for the year

Tax for the year comprises the current income tax for the year and changes in deferred tax and is recognised in the income statement with the share attributable to the net profit or loss for the year and directly in equity with the share attributable to entries directly in equity.

The company is subject to Danish rules on compulsory joint taxation of Danish group enterprises.

The current Danish income tax is allocated among the jointly taxed companies proportional to their respective taxable income (full allocation with reimbursement of tax losses).

Statement of financial position

Investments

Equity investment in group enterprise

Equity investment in group enterprise is measured at cost. If the recoverable amount is lower than the cost, writedown for impairment is done to match this lower value.

Accounting policies

Deposits

Deposits are measured at amortised cost and represent lease deposits, etc.

Receivables

Receivables are measured at amortised cost, which usually corresponds to nominal value.

In order to meet expected losses, impairment takes place at the net realisable value. The company has chosen to use IAS 39 as a basis for interpretation when recognising impairment of financial assets, which means that impairments must be made to offset losses where an objective indication is deemed to have occurred that an account receivable or a portfolio of accounts receivable is impaired. If an objective indication shows that an individual account receivable has been impaired, an impairment takes place at individual level.

Accounts receivable for which there is no objective indication of impairment at the individual level are evaluated at portfolio level for objective indication of impairment. The portfolios are primarily based on the debtors' domicile and credit rating in accordance with the company's and the group's credit risk management policy. Determination of the objective indicators applied for portfolios are based on experience with historical losses.

Impairment losses are calculated as the difference between the carrying amount of accounts receivable and the present value of the expected cash flows, including the realisable value of any securities received. The effective interest rate for the individual account receivable or portfolio is used as the discount rate.

Prepayments and accrued income

Prepayments and accrued income recognised under assets comprise incurred costs concerning the following financial year.

Cash on hand and demand deposits

Cash on hand and demand deposits comprise cash at bank and on hand.

Income tax and deferred tax

Current tax liabilities and current tax receivable are recognised in the statement of financial position as calculated tax on the taxable income for the year, adjusted for tax of previous years' taxable income and for tax paid on account.

The company is jointly taxed with consolidated Danish companies. The current corporate income tax is distributed between the jointly taxed companies in proportion to their taxable income and with full distribution with reimbursement as to tax losses. The jointly taxed companies are comprised by the Danish tax prepayment scheme.

According to the rules of joint taxation, Var2 Pharmaceuticals ApS is unlimitedly, jointly, and severally liable to pay the Danish tax authorities the total income tax, including withholding tax on interest, royalties, and dividends, arising from the jointly taxed group of companies.

Accounting policies

Deferred tax is measured on the basis of temporary differences in assets and liabilities with a focus on the statement of financial position. Deferred tax is measured at net realisable value.

Adjustments take place in relation to deferred tax concerning elimination of unrealised intercompany gains and losses.

Deferred tax is measured based on the tax rules and tax rates applying under the legislation prevailing in the respective countries on the reporting date when the deferred tax is expected to be released as current tax. Changes in deferred tax due to changed tax rates are recognised in the income statement, except for items included directly in the equity.

Deferred tax assets, including the tax value of tax losses allowed for carryforward, are recognised at the value at which they are expected to be realisable, either by settlement against tax of future earnings or by set-off in deferred tax liabilities within the same legal tax unit. Any deferred net tax assets are measured at net realisable value.

Liabilities other than provisions

Other liabilities concerning payables to suppliers, group enterprises, and other payables are measured at amortised cost which usually corresponds to the nominal value.

Accruals and deferred income

Payments received concerning future income are recognised under accruals and deferred income.

Income statement 1 January - 31 December

All amounts in DKK.

<u>Note</u>	<u>2020</u>	<u>2019</u>
Gross loss	-3.413.013	-4.729.732
1 Staff costs	-3.457.851	-3.521.375
Operating profit	-6.870.864	-8.251.107
Other financial income from group enterprises	211.459	146.649
Other financial income	0	12.412
Other financial costs	-374.054	-183.129
Pre-tax net profit or loss	-7.033.459	-8.275.175
2 Tax on net profit or loss for the year	1.642.988	1.424.371
Profit or loss from ordinary activities after tax	-5.390.471	-6.850.804
Net profit or loss for the year	-5.390.471	-6.850.804
Proposed appropriation of net profit:		
Allocated from retained earnings	-5.390.471	-6.850.804
Total allocations and transfers	-5.390.471	-6.850.804

Statement of financial position at 31 December

All amounts in DKK.

Assets		
<u>Note</u>	<u>2020</u>	<u>2019</u>
Non-current assets		
3 Concessions, patents, licenses, trademarks, and similar rights acquired	0	0
Total intangible assets	0	0
4 Equity investment in group enterprise	45.000	45.000
5 Deposits	13.131	13.131
Total investments	58.131	58.131
Total non-current assets	58.131	58.131
Current assets		
Trade debtors	518.109	0
Receivables from group enterprises	7.137.157	5.376.852
Other receivables	448.070	244.804
Prepayments and accrued income	1.145.137	262.630
Total receivables	9.248.473	5.884.286
Cash on hand and demand deposits	35.456.646	45.163.404
Total current assets	44.705.119	51.047.690
Total assets	44.763.250	51.105.821

Statement of financial position at 31 December

All amounts in DKK.

Equity and liabilities		
<u>Note</u>	<u>2020</u>	<u>2019</u>
Equity		
Contributed capital	100.925	100.925
Retained earnings	42.799.074	48.189.545
Total equity	42.899.999	48.290.470
Liabilities other than provisions		
Other payables	289.704	111.427
6 Total long term liabilities other than provisions	289.704	111.427
Trade payables	444.964	1.202.174
Other payables	1.125.417	1.501.750
Accrued expenses and deferred income	3.166	0
Total short term liabilities other than provisions	1.573.547	2.703.924
Total liabilities other than provisions	1.863.251	2.815.351
Total equity and liabilities	44.763.250	51.105.821

7 Contingencies

Statement of changes in equity

All amounts in DKK.

	Contributed capital	Retained earnings	Total
Equity 1 January 2019	100.925	55.040.350	55.141.275
Profit or loss for the year brought forward	0	-6.850.805	-6.850.805
Equity 1 January 2020	100.925	48.189.545	48.290.470
Profit or loss for the year brought forward	0	-5.390.471	-5.390.471
	100.925	42.799.074	42.899.999

Notes

All amounts in DKK.

	<u>2020</u>	<u>2019</u>
1. Staff costs		
Salaries and wages	3.270.292	3.278.926
Pension costs	133.797	177.829
Other costs for social security	25.844	25.844
Other staff costs	27.918	38.776
	<u>3.457.851</u>	<u>3.521.375</u>
Average number of employees	<u>8</u>	<u>8</u>
2. Tax on net profit or loss for the year		
Tax of the results for the year	-1.654.959	-1.424.371
Adjustment of tax for previous years	11.971	0
	<u>-1.642.988</u>	<u>-1.424.371</u>
	<u>31/12 2020</u>	<u>31/12 2019</u>
3. Concessions, patents, licenses, trademarks, and similar rights acquired		
Cost 1 January 2020	<u>86.486</u>	<u>86.486</u>
Cost 31 December 2020	<u>86.486</u>	<u>86.486</u>
Amortisation and writedown 1 January 2020	<u>-86.486</u>	<u>-86.486</u>
Amortisation and writedown 31 December 2020	<u>-86.486</u>	<u>-86.486</u>
Carrying amount, 31 December 2020	<u>0</u>	<u>0</u>
4. Equity investment in group enterprise		
Acquisition sum, opening balance 1 January 2020	<u>45.000</u>	<u>45.000</u>
Carrying amount, 31 December 2020	<u>45.000</u>	<u>45.000</u>

Notes

All amounts in DKK.

	<u>31/12 2020</u>	<u>31/12 2019</u>
5. Deposits		
Cost 1 January 2020	13.131	12.749
Additions during the year	<u>0</u>	<u>382</u>
Cost 31 December 2020	<u>13.131</u>	<u>13.131</u>
Carrying amount, 31 December 2020	<u>13.131</u>	<u>13.131</u>

6. Liabilities other than provision

	Total payables 31 Dec 2020	Current portion of long term payables	Long term payables 31 Dec 2020	Outstanding payables after 5 years
Other payables	<u>289.704</u>	<u>0</u>	<u>289.704</u>	<u>0</u>
	<u>289.704</u>	<u>0</u>	<u>289.704</u>	<u>0</u>

7. Contingencies

Contingent assets

A deferred tax asset of t.DKK 1.246 has not been recognised due to uncertainty regarding future usage.

Contingent liabilities

Rental liabilities

The company has entered into two tenancy agreements. The company has a rental commitment of t.DKK 135 as of 31 December 2020.

Collaborative research agreement

The company has entered into a collaborative research agreement. In the event of early termination, the company has a liability to pay all non-cancellable costs and liabilities relating to the project.

Joint taxation

With Oncomal ApS, company reg. no 34 58 03 67 as administration company, the company is subject to the Danish scheme of joint taxation and unlimitedly, jointly, and severally liable, along with the other jointly taxed companies, for the total corporation tax.

Notes

All amounts in DKK.

7. Contingencies (continued)

Joint taxation (continued)

The company is unlimitedly, jointly, and severally liable, along with the other jointly taxed companies, for any obligations to withhold tax on interest, royalties, and dividends.

The jointly taxed enterprises' total known net liability to the Danish tax authorities emerges from the financial statements of the administration company.

Any subsequent adjustments of corporate taxes or withholding tax, etc., may result in changes in the company's liabilities.